Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
International trade forum

Jiahui Health China Medical Tourism WTO Forum

Analysis based on 6 articles · First reported Sep 18, 2026 · Last updated Sep 18, 2026

Sentiment
10
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The event highlights a structural growth trend in China's healthcare and medical tourism sector, potentially benefiting hospital operators, insurers offering cross-border coverage, and pharmaceutical firms with China-only innovative therapies. Direct near-term market impact is limited as the forum is promotional and policy-dialogue oriented, but it signals regulatory momentum around visa facilitation and cross-border health data that could expand the addressable market for Chinese healthcare providers.

healthcare medical tourism pharmaceuticals

At the World Trade Organization Public Forum 2026 in Geneva, Dr. John K. Hsiang, Chairman of the Jiahui Health Executive Committee, presented China's expanding role in inbound medical tourism during the Health Without Borders session on Medical Tourism - Opportunities and Challenges in Services Trade. He was the sole Chinese healthcare representative invited to share China's experience in international medical services. According to data cited by Dr. Hsiang, China's leading hospitals serving international patients recorded 1.28 million international patient visits in 2025, up 73.6% from three years earlier, with 413,000 visits by patients who travelled to China specifically for medical care. Jiahui Health saw overseas patient inquiries nearly double year on year in the first half of 2026 and recorded more than 100,000 international outpatient visits in 2025. Growth is supported by China's 240-hour visa-free transit policy covering citizens of 57 countries through 65 ports, and by medical innovation: China now accounts for 33.7% of drugs in global development and in June 2026 approved the world's first CAR-T therapy for a solid tumor. Recent cases include a New Zealand patient with advanced gastric cancer who became the therapy's first international recipient in China — Shanghai, and a U.S. patient with non-small cell lung cancer who came to Jiahui for ivonescimab after discussions with a physician at MD Anderson Cancer Center. Dr. Hsiang positioned China — Shanghai as a gateway connecting Chinese medical innovation with global patients and called for greater international cooperation on medical travel, visa facilitation, information access, and regulatory dialogue on cross-border health data and telemedicine.

55 China approved CAR-T therapy
45 Jiahui Health treated international patients
40 China offered visa-free transit
30 John K. Hsiang called for cooperation
priv
Jiahui Health is the central presenter of the event, using the WTO forum to showcase its cross-border medical capabilities and nearly doubled overseas patient inquiries in H1 2026. The exposure could strengthen its brand as a gateway for international patients and support future patient volume growth.
Importance 90.0 Sentiment 30.0
per
As Chairman of the Jiahui Health Executive Committee, Dr. Hsiang was the sole Chinese healthcare representative at the session, presenting China's medical tourism momentum and calling for international cooperation on medical travel and visa facilitation.
Importance 85.0 Sentiment 25.0
cnt
China is the subject of the medical tourism growth story, supported by its 240-hour visa-free transit policy, 33.7% share of drugs in global development, and approval of the world's first CAR-T therapy for a solid tumor. The event reinforces its positioning as a leading destination for international medical care.
Importance 80.0 Sentiment 20.0
loc
China — Shanghai is positioned as the gateway city connecting Chinese medical innovation with global patients, hosting Jiahui Health and the first international recipient of the new CAR-T therapy.
Importance 45.0 Sentiment 15.0
alliance
The WTO hosted the Public Forum 2026 where the medical tourism session took place, providing the multilateral platform for the discussion on services trade in healthcare.
Importance 40.0 Sentiment 5.0
cnt
A U.S. patient with non-small cell lung cancer travelled to Jiahui Health to receive ivonescimab, an innovative bispecific antibody available only in China, illustrating inbound demand from developed markets.
Importance 15.0 Sentiment 5.0
cnt
A New Zealand patient with advanced gastric cancer travelled to China — Shanghai and became the first international recipient of China's newly approved CAR-T therapy for a solid tumor.
Importance 15.0 Sentiment 5.0
China strategic rival ↔ United States China views the United States as a strategic rival, actively competing across economic, technological, and military doma
China related ↔ New Zealand
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.